BVS: Bioventus Inc. Stock

by  •  • Comments Off on BVS: Bioventus Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 423.18
Enterprise Value ($M) 835.40
Book Value ($M) 217.43
Book Value / Share 3.41
Price / Book 1.95
NCAV ($M) -310.90
NCAV / Share -4.87
Price / NCAV -1.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.03
Return on Assets (ROA) -0.02
Return on Equity (ROE) -0.09

Liquidity (mrq)
Quick Ratio 0.97
Current Ratio 1.53

Balance Sheet (mrq) ($M)
Current Assets 265.90
Assets 794.24
Liabilities 576.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 512.35
Operating Income 8.49
Net Income -156.23

Cash Flow Statement (mra) ($M)
Cash From Operations 15.34
Cash from Investing 15.81
Cash from Financing -26.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Nantahala Capital Management, LLC 9.50 88.65
02-06 13G/A AMP-CF Holdings, LLC 5.17 0.00
01-22 13G/A Ew Healthcare Partners Acquisition Fund, L.p. 20.70 0.00
06-16 13D/A Juniper Investment Company, LLC 10.70 12.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-07 10-Q ‘ m` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 ☐ TRANSITION REP
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2023 ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-17 28,477 238,805 11.92
2024-05-16 58,556 139,164 42.08
2024-05-15 42,940 541,075 7.94
2024-05-14 19,303 390,789 4.94
2024-05-13 47,471 483,959 9.81

(click for more detail)

Similar Companies
ATEC – Alphatec Holdings, Inc. ATRI – Atrion Corporation
AXNX – Axonics, Inc. CUTR – Cutera, Inc.
CVRX – CVRx, Inc.


Financial data and stock pages provided by
Fintel.io